Concepedia

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

Rina Hui, Mustafa Özgüroğlu, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit,

The Lancet Oncology · 2019 · 192 citations · 22 references

DOIFull text

Open access

Concepts

References

22

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute · 1993 · 16K citations

, , +15

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.5K citations · Full text

, , +15

Interpreting the significance of changes in health-related quality-of-life scores.

David Osoba, George Rodrigues, James D. Myles et al. · Journal of Clinical Oncology · 1998 · 2.9K citations

, , +16

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

, , +17

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Pieter E. Postmus, Keith M. Kerr, Matthijs Oudkerk et al. · Annals of Oncology · 2017 · 2.3K citations · Full text

, , +14